Non-invasive Brain Stimulation Trial for High or Low Blood Pressure
Tests a non-invasive head stimulation method in adults with high or low blood pressure.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Regulation
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07239492, who can take part
Where in China
- Xuanwu Hospital, Capital Medical University, Beijing, Beijing 100053Beijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xuanwu Hospital, Beijing
- Trial code
- NCT07239492
- Record updated
- 20 November 2025
- Original description
The primary objective of this research is to study the efficacy and safety of temporal interference stimulation for regulating the blood pressure.Read full original descriptionShow less
Efficacy and Safety Evaluation of Transcranial Non-invasive Temporal Interference Stimulation for Blood Pressure Regulation: A Pilot, Prospective Study
The primary objective of this research is to study the efficacy and safety of temporal interference stimulation for regulating the blood pressure.
Inclusion: Age: 18-65 years old, male or female; Three groups of patients will be enrolled in the study:; Essential Hypertension Grade 1 (Low Risk) - Antihypertensive Medication-Naive Group: No other cardiovascular risk factors or disease history, with systolic blood pressure (SBP) ≥140 mmHg and <160 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg and <100 mmHg; Essential Hypertension - Refractory Hypertension Group: Meeting one of the following conditions after intensive lifestyle intervention plus taking 3 different types of antihypertensive drugs (including thiazide diuretics) for ≥4 weeks, with each drug at the maximum dose or maximum tolerated dose: Clinic blood pressure ≥140/90 mmHg and 24-hour average ambulatory blood pressure ≥130/80 mmHg, or average home blood pressure ≥135/85 mmHg; or blood pressure can only be controlled below 140/90 mmHg with ≥4 types of antihypertensive drugs; Neurogenic Orthostatic Hypotension (nOH) Group: A decrease in SBP ≥20 mmHg and/or DBP ≥10 mmHg within 3 minutes of the head-up tilt test (HUTT) and/or standing activity; BMI: 18-30; After being informed of the potential risks, the patient agrees to participate in this study and signs the informed consent form (ICF).
Exclusion: Patients with secondary hypertension; Individuals unable to cooperate due to mental illness or other reasons; Patients with cardiac insufficiency; Individuals with a high risk of cerebrovascular disease confirmed by transcranial magnetic resonance imaging (MRI); Patients with intracranial structural lesions (e.g., infarcts, vascular malformations, space-occupying lesions, etc.); Pregnant women; Those who have participated in other clinical studies within the past 3 months; Patients who apply to withdraw from this clinical study for any reason; Patients excluding those with white coat effect.